Glancy Binkow & Goldberg LLP Announces Continued Investigation of Physicians Formula Holdings, Inc.
August 22 2012 - 4:52PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims against the Board of Directors of
Physicians Formula Holdings, Inc. (“Physicians Formula” or the
“Company”) (NASDAQ: FACE) related to the sale of the Company to
Swander Pace Capital. The transaction is valued at approximately
$65 million or $4.25 per share.
This investigation concerns whether the Board of Directors of
Physicians Formula breached their fiduciary duties to stockholders
by failing to adequately shop the Company before agreeing to enter
into the proposed transaction, and whether the Company has
disclosed all material information to shareholders about the
transaction. At least one analyst has set a target price for the
Company’s stock at $5.00 per share.
If you are a shareholder of Physicians Formula, if you have
information or would like to learn more about our investigation, or
if you wish to discuss these matters or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Louis Boyarsky, Esquire,
Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite
2100, Los Angeles, CA 90067, by telephone at 310-201-9150 or
Toll-Free at 888-773-9224 or by email to
shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Physicians Formula Holdings, Inc. (MM) (NASDAQ:FACE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Physicians Formula Holdings, Inc. (MM) (NASDAQ:FACE)
Historical Stock Chart
From Apr 2023 to Apr 2024